Holmes Biopharma, Inc.: Largest Single Contract to Date

SCOTTSDALE, ARIZONA announces the signing of a $1.6 million contract with a major biotech company for conducting a Phase 1 trial at the company's facility in Omaha, Nebraska. This is the largest single contract signed to date, and brings the total of committed contracts in 2007 to $13 million.

"This large contract and our first years sales results are evidence that our aggressive growth strategy for 2008 is well under way, and reaffirms the confidence our clients have in our clinical research work," stated John Metcalfe, CEO of Holmes Biopharma Inc.

About Holmes:

Holmes Biopharma Inc. and it's wholly owned subsidiary, Qualia Clinical Service, Inc. is a contract research organization focused on providing integrated and cost effective clinical development services. Currently, clinics operate in Omaha, Nebraska, USA, Toronto, Canada, and Kiev, Ukraine, Eastern Europe. For more information about the company please visit our website at www.holmesbiopharma.com.

On behalf of the Board of Directors

John F. Metcalfe, President, CEO

Certain statements in this press release constitute "forward looking statements" within the meaning of the United States Securities Legislation. The Company's actual results could differ from those in the forward-looking statements. Do not construe this information as investment advice. This is not a solicitation to buy or sell securities. This does not purport to be a complete analysis of the Company. Investing in securities is speculative and carries a high degree of risk. Past performance does not guarantee future results. Readers should consult their own independent advisers with any investment, including any contemplated investment. All information contained in this press release should be independently investigated. This press release contains forward-looking statements. These remarks involve risks and uncertainties. Risks are not limited to quarterly fluctuations in results or the companies' management of growth and competition. Other risks are detailed in the Company's SEC filings. Actual results may differ materially from such information set forth herein.

Contacts: Holmes Biopharma, Inc. John F. Metcalfe President, CEO 1-800-778-4990 Email: ir@holmesbiopharma.com Website: www.holmesbiopharma.com

Swiftsure (CE) (USOTC:HLMB)
過去株価チャート
から 5 2024 まで 5 2024